Avalo Therapeutics (NASDAQ:AVTX) Earns Buy Rating from Analysts at Stifel Nicolaus

Investment analysts at Stifel Nicolaus started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research note issued to investors on Tuesday, MarketBeat reports. The firm set a “buy” rating and a $36.00 price target on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 330.62% from the stock’s current price.

AVTX has been the subject of several other reports. Piper Sandler initiated coverage on Avalo Therapeutics in a report on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price for the company. Wedbush reissued an “outperform” rating and set a $18.00 target price on shares of Avalo Therapeutics in a research note on Thursday, March 20th. HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, BTIG Research initiated coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $40.00 price target for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $33.00.

Avalo Therapeutics Stock Down 2.1 %

Shares of AVTX opened at $8.36 on Tuesday. The firm’s fifty day moving average is $7.55 and its two-hundred day moving average is $9.13. Avalo Therapeutics has a 52-week low of $4.60 and a 52-week high of $34.46.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors have recently added to or reduced their stakes in AVTX. RA Capital Management L.P. acquired a new stake in Avalo Therapeutics during the 3rd quarter worth $9,186,000. Ikarian Capital LLC increased its holdings in shares of Avalo Therapeutics by 1,673.0% in the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after acquiring an additional 915,629 shares during the period. Affinity Asset Advisors LLC grew its position in Avalo Therapeutics by 1,123.9% during the 4th quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock worth $4,092,000 after purchasing an additional 505,765 shares during the last quarter. Velan Capital Investment Management LP purchased a new stake in shares of Avalo Therapeutics in the fourth quarter valued at about $817,000. Finally, Geode Capital Management LLC grew its holdings in shares of Avalo Therapeutics by 937.0% during the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after buying an additional 94,742 shares during the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.